

FORM PTO-1449	Atty. Docket No.: U16.12-0006	Appl. No.: 10/566,785
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	First Named Inventor:	
	Jacques-Philippe Moulinoux et al.	
	Filing Date	Group Art:
	1/31/06	

U.S. PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Name	Class	Sub Class	Filing Date If Appropriate
AA	6,114,392	9/5/00	Gilad et al.	514	634	
AB						
AC						
AD						
AE						

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub Class	Translation Yes No
AF	EP 1 085 011	9/15/00	EPO			X
AG	WO 03/051348 A2	6/26/03	PCT			X
AH	WO 95/00042	1/5/95	PCT			(Abstract)
AI	WO 95/00041	1/5/95	PCT			(Abstract)

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AJ	G.M. Gilad et al., "Novel Polyamine Derivatives as Neuroprotective Agents," The Journal of Pharmacology and Experimental Therapeutics, XP-002271148, 10/1999, pp.39-43.
AK	G.M. Gilad et al., "Early Polyamine Treatment Enhances Survival of Sympathetic Neurons after Postnatal Axonal Injury or Immunosympathectomy," Developmental Brain Research, XP-002271146, Vol. 38, No. 2, 1988, pp. 175-181.
AL	G.M. Gilad et al., "Treatment with Polyamines can Prevent Monosodium Glutamate Neurotoxicity in the Rat Retina," Life Science, Vol. 44, No. 25, XP-002271147, 1989, pp. 1963-1969.
AM	S. Kergozien et al., "Polyamine Deprivation Provokes an Antalgic Effect," Life Sciences, Vol. 58, No. 24, XP-002309789, 1996, pp. 2209-2215.

EXAMINER: /Kortney Klinkel/

DATE CONSIDERED: 10/29/2009

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KLK/